Background Hemolytic disease of the fetus and newborn is a public health problem caused by maternal-fetal incompatibility; no prophylaxis is available for most alloantibodies that induce this disease.

Objective To evaluate the knowledge of pregnant women and the clinical management of hemolytic disease of the fetus and newborn, as well as to describe the gestational profile, risk factors and ...

Practice patterns vary widely for management of hemolytic disease of the fetus and newborn (HDFN). Researchers are calling for standardized guidelines to manage neonates with HDFN. Postnatal ...

Considerable variations have been observed in the postnatal management and outcomes of hemolytic disease of the fetus and ...

In pregnancies at risk of hemolytic disease of the fetus and newborn (HDFN), amniocentesis is used to identify the fetus’s ...

A RECENT international cohort study has revealed significant variations in the postnatal management and outcomes of haemolytic disease of the foetus and newborn (HDFN) across 31 expert centres in 22 ...

If Neanderthal women mated with Homo sapiens or Denisovan men, there was a high risk of newborns having neonatal hemolytic ...

Natera (NTRA), announced a new policy for commercial coverage of its cfDNA Fetal RhD noninvasive prenatal test, Fetal RhD NIPT from one of the ...

Homozygosity has been assumed for the sibling and the 2 cousins of the proposita, all of whom are now deceased and had hemolytic disease. Other studies. Addition of crystalline triosephosphate ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new policy for ...